C. Andrews

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders

A. Giobbie-Hurder, F. Hodi, U. Kaiser, 2019, Cancer Immunology Research.

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

E. Winer, L. Trippa, J. Bellon, 2020, Clinical breast cancer.

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.

E. Winer, L. Trippa, W. Barry, 2019, Clinical breast cancer.

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.

E. Winer, L. Trippa, E. V. Van Allen, 2020, JAMA oncology.

A phase I dose-escalation trial of radiation therapy and concurrent cisplatin for stage II and III triple-negative breast cancer.

E. Winer, J. Bellon, A. Taghian, 2021, International journal of radiation oncology, biology, physics.

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).

E. Winer, L. Trippa, D. Dillon, 2019, Journal of Clinical Oncology.

Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations

David R. Liu, E. Winer, G. Shapiro, 2019, Clinical Trials.

Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.

E. Winer, L. Trippa, H. Rugo, 2019, Journal of Clinical Oncology.